Haemonetics Corporation (HAE) Position Decreased by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio cut its holdings in shares of Haemonetics Corporation (NYSE:HAE) by 2.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,552 shares of the medical instruments supplier’s stock after selling 74 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Haemonetics Corporation were worth $101,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Verition Fund Management LLC acquired a new position in shares of Haemonetics Corporation during the 2nd quarter worth approximately $452,000. Piedmont Investment Advisors LLC acquired a new position in shares of Haemonetics Corporation during the 2nd quarter worth approximately $448,000. Susquehanna International Group LLP acquired a new position in shares of Haemonetics Corporation during the 2nd quarter worth approximately $445,000. The Manufacturers Life Insurance Company increased its holdings in shares of Haemonetics Corporation by 1.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 39,906 shares of the medical instruments supplier’s stock worth $1,575,000 after acquiring an additional 488 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of Haemonetics Corporation during the 2nd quarter worth approximately $6,115,000.

Haemonetics Corporation (NYSE:HAE) opened at $57.70 on Tuesday. The company has a quick ratio of 1.51, a current ratio of 2.17 and a debt-to-equity ratio of 0.22. Haemonetics Corporation has a 1-year low of $36.44 and a 1-year high of $58.23. The company has a market capitalization of $3,062.93, a price-to-earnings ratio of 35.58, a price-to-earnings-growth ratio of 4.36 and a beta of 0.91.

Haemonetics Corporation (NYSE:HAE) last issued its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.07. Haemonetics Corporation had a return on equity of 11.16% and a net margin of 0.50%. The firm had revenue of $225.40 million for the quarter, compared to analyst estimates of $219.12 million. During the same period in the prior year, the firm posted $0.38 EPS. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. equities research analysts predict that Haemonetics Corporation will post 1.7 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Haemonetics Corporation (HAE) Position Decreased by Public Employees Retirement System of Ohio” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://sportsperspectives.com/2017/11/21/haemonetics-corporation-hae-position-decreased-by-public-employees-retirement-system-of-ohio.html.

In other news, Director Susan Bartlett Foote sold 16,926 shares of the company’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $54.19, for a total transaction of $917,219.94. Following the completion of the sale, the director now directly owns 27,313 shares in the company, valued at approximately $1,480,091.47. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Ronald G. Gelbman sold 5,440 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $56.69, for a total value of $308,393.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 40,250 shares of company stock valued at $2,196,240. Corporate insiders own 1.20% of the company’s stock.

HAE has been the topic of a number of recent analyst reports. BidaskClub lowered Haemonetics Corporation from a “sell” rating to a “strong sell” rating in a report on Thursday, July 27th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $48.00 price objective on shares of Haemonetics Corporation in a report on Thursday, July 27th. Barrington Research raised Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 price objective on the stock in a report on Tuesday, August 8th. TheStreet raised Haemonetics Corporation from a “c” rating to a “b-” rating in a report on Monday, August 7th. Finally, Zacks Investment Research raised Haemonetics Corporation from a “hold” rating to a “buy” rating and set a $47.00 price objective on the stock in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $53.33.

Haemonetics Corporation Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply